Uncategorized
Evolving cross-linking techniques treating wider range of keratoconus patients
Corneal cross-linking, or CXL, is enjoying its 10th anniversary of broad clinical use since the pioneering work of Seiler and Mrochen. In most parts of the world, CXL is approved, available and standard of care for treating the patient with keratoconus. In the U.S., CXL is still not approved by the U.S. Food and Drug Administration, but many of us are hoping this will change in 2015 if Avedro is successful in achieving approval for the so-called standard epithelium-off Dresden protocol.